Navigation Links
New Published Study Finds Masimo SET® Delivers More Reliable Measurements Significantly Faster Than Other Pulse Oximetry Technologies
Date:4/11/2011

or in the Neonatal Intensive Care Unit (NICU). Using the Masimo LNOP® sensor with the Radical-7, the E630 sensor with the Ohmeda Biox 3700, and the OxiMax Max-N sensor for the Nellcor N395, the time to a reliable SpO2 measurement was recorded post-ductally (one sensor placed on each foot) once an adequate pulse rate signal was displayed.  Results showed that "the pulse oximeter with Masimo SET provided the fastest response time."  In the first comparison of 17 infants, the median response time to obtain a reliable measurement for the Masimo Radical-7 was 20.2+6 (with a range of 18-26 seconds) versus 74.2+12 (with a range of 38-98 seconds) for the Ohmeda Biox 3700.  In the second comparison of 15 infants, the median response time for the Masimo Radical-7 was 20.9+4 (with a range of 19-28 seconds) versus 67.3+21 (with a range of 40-90 seconds) for the Nellcor N-395.

Finding that "there are significant differences in the response of pulse oximeters during neonatal resuscitation," researchers concluded that "the speed and reliability of the Masimo SET technology can be of help for clinicians to more accurately adjust the fraction of inspired oxygen during newborn resuscitations, thus preventing or minimizing damage secondary to unnecessary exposure of oxygen and hyperoxemia and to wide fluctuations in oxygen levels."  

The 'gold standard' Measure-Through Motion and Low Perfusion performance of Masimo SET® has been shown in over 100 independent clinical studies to provide the most accurate and trustworthy measurements -- even under the most challenging clinical conditions, including patient motion and low perfusion.  

(1) Baquero H, Alviz R, Castillo A, Neira F, Sola A.  "Avoiding Hyperoxemia During Neonatal Resuscitation:  Time To Response Of Different SpO2 Monitors."  Acta Paed April 2011 Vol. 100, Issue
'/>"/>

SOURCE Masimo Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in Headache
2. Research on Crucial Role of PET-Guided Biopsy in Initial Breast Cancer Diagnosis and Presurgical Planning Published in The Breast Journal
3. Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeichs Genous™ Stent in Diabetic Patients
4. Positive Findings From Excellagen Matrix Clinical Study Published in Peer-Reviewed Journal Wound Repair and Regeneration
5. German High Court Rules in Favor of AmniSure® as New European Guidelines Published
6. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
7. Analysis of Calipers Phase I EPA ToxCast™ Data Published in Leading Scientific Journal
8. Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeichs Genous™ Stent
9. Caldolor® Rapid Infusion Shown to be Safe and Well Tolerated in Newly Published Clinical Study
10. CHAMPION Study Published in The Lancet
11. Data on DermTechs Non-invasive Test for Melanoma Are Published in the British Journal of Dermatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Medtronic,s roughly $43 billion acquisition and ... in the media for its US Federal tax ... player in one of the fastest growing device ... research firm said  the two companies compete in ... of solutions spanning inpatient to home care, and ...
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, ... Distinguished Preceptorship Award from The American Association ... the advancement of nurse practitioners. The Distinguished Preceptorship ... had made a significant contribution toward increasing the ... of Nurse Practitioners (AANP) is the largest full-service ...
(Date:11/26/2014)... Nov. 25, 2014 (HealthDay News) -- Youngsters who enter ... new study suggests. Early puberty was linked with ... poor self-image and high anxiety levels, according to the ... such as conflict with family and peers, and having ... study found. Although the study found an association ...
(Date:11/26/2014)... TUESDAY, Nov. 25, 2014 (HealthDay News) -- Teens ... likely to abuse those drugs than other teens, ... the need to conduct substance abuse assessments on ... researchers said. "Prescribers and parents don,t realize ... a professor at the University of Michigan School ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Exposure to peanut protein ... allergy in infants with the skin condition eczema, a ... children in the United States are allergic to peanuts. ... food allergies, particularly peanut allergy, the researchers noted. ... to 15 months. The researchers examined the amount of ...
(Date:11/26/2014)... Randy Dotinga HealthDay Reporter ... drugs such as Prilosec and Nexium may disrupt the makeup ... of infections and other problems, a small new study suggests. ... it more likely users will become ill, and study authors ... inhibitors. However, these antacids "should be used at the ...
Breaking Medicine News(10 mins):Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
... patients with the blood cancer , , WEDNESDAY, July 9 ... once-banned drug thalidomide for patients with myeloma have learned ... is to science: Don,t judge results too early. , ... increased the odds of a complete remission, but not ...
... Weight Watchers,International, Inc. (NYSE: WTW ) will release ... close on Thursday, July 31, 2008., The Company ... at 5:00,p.m. ET. During the conference call, David Kirchhoff, ... Officer, will discuss,second quarter results and answer questions from ...
... its,efforts to ensure the State,s leaders are putting patients ... for Patient Care (CPC), a,non-profit, patient-advocacy organization, hand delivered ... as other key leaders in the,State Legislature today., ... with a better,understanding of how devastating these massive health ...
... be done without destroying embryo , , WEDNESDAY, July 9 ... in developing human embryonic stem cells earlier in the ... embryo, so the whole embryo is not destroyed. , ... European Society of Human Reproduction & Embryology annual conference ...
... Pain Centers (SCPC) have been shown to perform better ... for Medicare and Medicaid Services (CMS) as compared to ... an Emory University researcher. , The findings, ... for observation medicine in the Emory University School of ...
... Holdings, Inc.,(NYSE and SWX: ZMH) announced today its second ... live over the Internet on,Thursday, July 24, 2008, at ... results will be made available at 7:00 a.m. the,morning ... can be accessed via Zimmer,s Investor Relations,website at ...
Cached Medicine News:Health News:Thalidomide Continues to Show Benefits Against Myeloma 2Health News:Thalidomide Continues to Show Benefits Against Myeloma 3Health News:Weight Watchers Announces Second Quarter 2008 Earnings Conference Call 2Health News:CPC Hand-Delivers Patient Testimonies to State Leaders Pleading for No Budget Cuts to Health and Human Services 2Health News:New Technique Harvests Stem Cells at Earlier Stage 2Health News:New Technique Harvests Stem Cells at Earlier Stage 3Health News:Chest pain center accreditation linked with better outcomes in heart attack patients 2
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
... proBNP assay is a rapid and accurate bedside ... system assisting the diagnosis and assessment of patients ... both speed and accuracy profit from ... proBNP assay = 12 minutes. In emergency departments ...
Medicine Products: